As the level of patient risk under the current regulatory pathways remains uncertain, future research should compare AI/ML-enabled device recall rates across jurisdictions to assess whether AI-specific regulatory frameworks improve patient safety and device reliability.
Bracken et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: